Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Few Physicians Favor Payment Plan Changes

Value Based Payment (VBP), where health care purchasers and payers pay based upon the quality and outcomes of care, is a relatively new way to pay for healthcare that faces considerable opposition from physicians, who think it won’t have any effect on care or controlling costs. In fact, according to FHMA, in a Leavitt Partners…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Value Based Payment (VBP), where health care purchasers and payers pay based upon the quality and outcomes of care, is a relatively new way to pay for healthcare that faces considerable opposition from physicians, who think it won’t have any effect on care or controlling costs. In fact, according to FHMA, in a Leavitt Partners survey of 621 physicians, “Only one-fifth of physicians thought either bundled payments or hospital-led accountable care organizations (ACOs) would contain healthcare costs,” and “Similarly, few thought patient health improvements likely would result from bundled payments (19 percent), ACOs (29 percent), or episode-based payments (29 percent).”

In fact, many physicians are unaware that of the kinds of payments their hospitals handle, including ACOs and bundled payments. “Pluralities of physicians were uncertain about the patient health benefits of ACOs (46 percent), bundled payments (48 percent), capitated payments (45 percent), and patient-centered medical homes (46 percent). And majorities were uncertain about the health benefits of integrated delivery networks (56 percent), episode-based payments (55 percent), and global payments (58 percent).” Among those who were aware of the kinds of payments their hospitals accepted, most were still opposed—primarily because the payment plans were new and they didn’t like how their payments were affected.

This doesn’t mean physicians don’t have their own ideas about what would make for better payment plans. These same physicians preferred payment plans with “physician pay for performance (40 percent) and patient-centered medical homes (40 percent).” They also thought that “an increased focus on wellness and prevention (60 percent), improved management of mental health (56 percent), and better management of heavy utilizers of care (52 percent)” were more likely to contain costs.

Overall, doctor opposition to these new payment plans seem to stem primarily from uncertainty—uncertainty of how they would work, uncertainty in the middle of massive and ongoing changes in health care payment plans from both the government and private sector, and uncertainty of how and how much they would get paid for services. All of this uncertainty drives much of the doctor opposition to the changes taking place. Some simply don’t have the time to learn about all the intricacies around payment plans.

For many of these payment plans to succeed, physician buy-in—even grudging buy-in—is absolutely necessary. For third party payers to get physicians onboard, there needs to be more outreach to physicians to educate them about what these payment changes mean for both patient care and doctor remuneration. For doctors who have been working in the old system for decades, it will likely take longer to persuade them these plans are to everyone’ benefit—if they are ever persuaded.

Most people don’t like change, nor to have their expectations altered, and doctors are certainly no different in this matter. Perhaps less so, given the fact they would much prefer to simply see patients and not have to be bothered by payment plans. But so long as changes are occurring which affect what they can do and how much they are paid, they are going to be bothered by these ongoing changes.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512